CEL-SCI (NYSE:CVM) Now Covered by StockNews.com

StockNews.com began coverage on shares of CEL-SCI (NYSE:CVM) in a research note published on Tuesday morning. The firm issued a sell rating on the stock.

CEL-SCI Stock Down 8.9 %

CEL-SCI stock opened at $0.36 on Tuesday. The stock has a market capitalization of $27.68 million, a PE ratio of -0.75 and a beta of 0.69. CEL-SCI has a 12 month low of $0.33 and a 12 month high of $2.50. The business has a 50 day simple moving average of $0.45 and a 200-day simple moving average of $0.75. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.07 and a quick ratio of 1.09.

Hedge Funds Weigh In On CEL-SCI

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CVM. Plotkin Financial Advisors LLC acquired a new position in CEL-SCI during the third quarter worth $98,000. Geode Capital Management LLC boosted its stake in CEL-SCI by 9.6% during the third quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock worth $650,000 after buying an additional 53,879 shares during the last quarter. Finally, Thoroughbred Financial Services LLC boosted its stake in CEL-SCI by 40.1% during the fourth quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock worth $76,000 after buying an additional 54,900 shares during the last quarter. Institutional investors and hedge funds own 12.08% of the company’s stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.